Treatment for Epilepsy

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Epilepsy+1 More
Eligibility
6 - 17
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a pharmaceutical-grade cannabidiol called Epidiolex can help treat anxiety in children with epilepsy that hasn't responded well to other medications.

Eligible Conditions
  • Epilepsy
  • Anxiety

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
Empagliflozin 25 mg
1
Recombinant human hyaluronidase PH20 (rHuPH20)
1
IP

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 16 weeks

16 weeks
CGI-I

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Empagliflozin 25 mg
1
Recombinant human hyaluronidase PH20 (rHuPH20)
1
IP

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 16 weeks

Who is running the clinical trial?

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Lead Sponsor
82 Previous Clinical Trials
24,468 Total Patients Enrolled
1 Trials studying Epilepsy
20 Patients Enrolled for Epilepsy
Jay SalpekarPrincipal InvestigatorPrincipal Investigator

Eligibility Criteria

Age 6 - 17 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are sexually active, must agree to sexual abstinence, or, to use an approved birth control method for the full duration of study participation.
You are male or female and aged between 6 and 18 years.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top